News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
466,882 Results
Type
Article (28561)
Company Profile (319)
Press Release (437995)
Multimedia
Podcasts (88)
Webinars (14)
Section
Business (126373)
Career Advice (311)
Deals (21167)
Drug Delivery (61)
Drug Development (64396)
Employer Resources (45)
FDA (9103)
Job Trends (7343)
News (218861)
Policy (17094)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Standard (3)
Academia (1346)
Accelerated approval (28)
Adcomms (15)
Allergies (125)
Alliances (35475)
ALS (152)
Alzheimer's disease (1228)
Antibody-drug conjugate (ADC) (306)
Approvals (9405)
Artificial intelligence (398)
Autoimmune disease (165)
Automation (26)
Bankruptcy (166)
Best Places to Work (6202)
BIOSECURE Act (6)
Biosimilars (128)
Biotechnology (244)
Bladder cancer (149)
Brain cancer (57)
Breast cancer (536)
Cancer (4334)
Cardiovascular disease (337)
Career advice (273)
Career pathing (10)
CAR-T (276)
CDC (13)
Celiac Disease (1)
Cell therapy (697)
Cervical cancer (22)
Clinical research (55481)
Collaboration (1510)
Company closure (2)
Compensation (865)
Complete response letters (51)
COVID-19 (2282)
CRISPR (96)
C-suite (741)
Cystic fibrosis (134)
Data (5664)
Denatured (17)
Depression (118)
Diabetes (339)
Diagnostics (3175)
Digital health (28)
Diversity (6)
Diversity, equity & inclusion (13)
Drug discovery (231)
Drug pricing (77)
Drug shortages (9)
Duchenne muscular dystrophy (233)
Earnings (44163)
Editorial (34)
Employer branding (6)
Employer resources (44)
Events (84191)
Executive appointments (835)
FDA (11629)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1312)
Gene editing (202)
Generative AI (29)
Gene therapy (567)
GLP-1 (664)
Government (2099)
Grass and pollen (7)
Guidances (292)
Healthcare (9203)
HIV (52)
Huntington's disease (47)
IgA nephropathy (85)
Immunology and inflammation (229)
Immuno-oncology (59)
Indications (105)
Infectious disease (2492)
Inflammatory bowel disease (182)
Inflation Reduction Act (12)
Influenza (92)
Intellectual property (212)
Interviews (48)
IPO (9789)
IRA (18)
Job creations (1554)
Job search strategy (242)
JPM (49)
Kidney cancer (14)
Labor market (31)
Layoffs (299)
Leadership (10)
Legal (3393)
Liver cancer (66)
Longevity (15)
Lung cancer (598)
Lymphoma (371)
Machine learning (29)
Management (11)
Manufacturing (557)
MASH (157)
Medical device (4922)
Medtech (4945)
Mergers & acquisitions (12259)
Metabolic disorders (947)
mRNA (149)
Multiple sclerosis (145)
NASH (16)
Neurodegenerative disease (285)
Neuropsychiatric disorders (80)
Neuroscience (2350)
Neurotech (1)
NextGen: Class of 2026 (2881)
Non-profit (1322)
Now hiring (32)
Obesity (434)
Opinion (208)
Ovarian cancer (159)
Pain (148)
Pancreatic cancer (208)
Parkinson's disease (276)
Partnered (19)
Patents (391)
Patient recruitment (457)
Peanut (52)
People (46328)
Pharmaceutical (47)
Pharmacy benefit managers (15)
Phase 1 (18579)
Phase 2 (25313)
Phase 3 (17096)
Pipeline (4729)
Policy (126)
Postmarket research (1501)
Preclinical (7679)
Press Release (40)
Prostate cancer (215)
Psychedelics (50)
Radiopharmaceuticals (260)
Rare diseases (799)
Real estate (2832)
Recruiting (20)
Regulatory (14997)
Reports (23)
Research institute (1336)
Resumes & cover letters (38)
Rett syndrome (24)
RNA editing (21)
RSV (52)
Schizophrenia (137)
Series A (223)
Series B (205)
Service/supplier (2)
Sickle cell disease (97)
Special edition (19)
Spinal muscular atrophy (132)
Sponsored (22)
Startups (3032)
State (1)
Stomach cancer (9)
Supply chain (62)
Tariffs (36)
The Weekly (70)
Vaccines (700)
Venture capital (79)
Weight loss (236)
Women's health (55)
Worklife (2)
Date
Today (143)
Last 7 days (582)
Last 30 days (2073)
Last 365 days (24314)
2026 (3545)
2025 (24627)
2024 (25871)
2023 (27431)
2022 (35027)
2021 (38117)
2020 (33282)
2019 (21716)
2018 (16096)
2017 (22103)
2016 (22759)
2015 (28107)
2014 (21392)
2013 (17607)
2012 (18078)
2011 (17822)
2010 (16311)
Location
Africa (377)
Alabama (74)
Alaska (2)
Arizona (142)
Arkansas (11)
Asia (29137)
Australia (4746)
California (9569)
Canada (2511)
China (955)
Colorado (348)
Connecticut (422)
Delaware (321)
Europe (67063)
Florida (1253)
Georgia (278)
Hawaii (3)
Idaho (28)
Illinois (697)
India (50)
Indiana (265)
Iowa (14)
Japan (365)
Kansas (100)
Kentucky (23)
Louisiana (13)
Maine (15)
Maryland (1020)
Massachusetts (7095)
Michigan (175)
Minnesota (369)
Mississippi (3)
Missouri (81)
Montana (17)
Nebraska (8)
Nevada (86)
New Hampshire (36)
New Jersey (2546)
New Mexico (15)
New York (2472)
North Carolina (1082)
North Dakota (8)
Northern California (4668)
Ohio (246)
Oklahoma (12)
Oregon (29)
Pennsylvania (1661)
Puerto Rico (12)
Rhode Island (31)
South America (655)
South Carolina (14)
Southern California (3790)
Tennessee (81)
Texas (1355)
United States (32180)
Utah (163)
Virginia (224)
Washington D.C. (52)
Washington State (754)
West Virginia (2)
Wisconsin (113)
Wyoming (1)
466,882 Results for "amarna therapeutics b v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes
July 9, 2025
·
5 min read
Business
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type 1 Diabetes Mellitus, announces the appointment of Aurelia Caparrós as the Company’s new Chief Business Officer, effective 1st of April 2024.
April 19, 2024
·
3 min read
Press Releases
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
January 7, 2026
·
3 min read
Business
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
Amarna Therapeutics, a privately-held biotechnology company focused on developing transformative gene therapies for a range of rare and prevalent genetic diseases, including Type 1 Diabetes Mellitus, is pleased to announce the formation of its new Scientific Advisory Board. The newly established SAB consists of seven distinguished international scientific opinion leaders.
June 17, 2024
·
7 min read
Press Releases
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
December 4, 2024
·
5 min read
Press Releases
RadioMedix Expands Thorium-228 Supply Network Through New Agreement With Van Overeem Nuclear B.V.
December 15, 2025
·
3 min read
Press Releases
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
November 3, 2025
·
3 min read
Press Releases
Primmune Therapeutics Announces Additional Close of Series B Financing
January 27, 2026
·
2 min read
Press Releases
Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease
December 11, 2024
·
4 min read
Press Releases
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
December 4, 2025
·
10 min read
1 of 46,689
Next
